Isolation and Identification of 3,4-Seco-Solanidine-3,4-dioic acid (SSDA) as a Urinary Biomarker of Cytochrome P450 2D6 (CYP2D6) Activity

Andrew C Behrle¹, Justin Douglas, J. Steven Leeder and Leon van Haandel²

Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, and Children’s Mercy Research Institute, Children’s Mercy Kansas City, Kansas City MO 64108, USA (A.C.B., J.S.L., L.vH.); Nuclear Magnetic Resonance Core Lab, University of Kansas, Lawrence, KS 66045, USA (J.D.), and Schools of Medicine and Pharmacy, University of Missouri-Kansas City, Kansas City, MO, 64108, USA (J.S.L.)
Running Title: Identification of SSDA as a Biomarker of CYP2D6 Activity

Corresponding author:

J Steven Leeder, PharmD, PhD
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation
Department of Pediatrics
Children’s Mercy Kansas City
2401 Gillham Road
Kansas City, MO   64108
Email: sleeder@cmh.edu
Phone: (816) 731-7116
Fax: (816) 302-9943
ORCID # 0000-0001-6688-0504

Number of text pages: 16
Number of tables: 3
Number of figures: 4
Number of references: 34
Number of words in the Abstract: 243
Number of words in the Introduction: 606
Number of words in the Discussion: 1040

Non-standard abbreviations: 1D, one dimensional; 2D, two dimensional; CYP2D6, cytochrome P450 2D6; COSY, ¹H-¹H correlation spectroscopy; DEPT, distortionless enhancement by polarization transfer; DEPT90, DEPT with a final proton pulse angle of 90°;
DEPT135, DEPT with a final proton pulse angle of 135°; HMBC, heteronuclear multiple-bond correlation; HSQC, heteronuclear single quantum correlation; TOCSY, total correlation spectroscopy; HSQC-TOCSY, heteronuclear single quantum correlation with additional total correlation spectroscopy transfer; qToF, quadropole time-of-flight mass spectrometry;

**Keywords** Cytochrome P450 2D6; CYP2D6; urinary biomarker; solanidine, 3,4-seco-solanidine-3,4-dioic acid, metabolite structure identification; urinary metabolite ratio; phenotype
Abstract

Cytochrome P450 2D6 (CYP2D6), is responsible for the metabolism and elimination of approximately 25% of clinically used drugs, including antidepressants and antipsychotics, and its activity varies considerably on a population basis primary due to genetic variation. CYP2D6 phenotype can be assessed in vivo following administration of an exogenous probe compound, such as dextromethorphan or debrisoquine, but use of a biomarker that does not require administration of an exogenous compound (i.e., drug) has considerable appeal for assessing CYP2D6 activity in vulnerable populations, such as children. The goal of this study was to isolate, purify and identify an "endogenous" urinary biomarker (M1; m/z 444.3102) of CYP2D6 activity reported previously. Several chromatographic separation techniques (reverse phase HPLC, cation exchange and analytical reverse phase UPLC) were used to isolate and purify 96 μg of M1 from 40 L of urine. Subsequently, 1D and 2D NMR, and functional group modification reactions were used to elucidate its structure. Analysis of mass spectrometry and NMR data revealed M1 to have similar spectroscopic features to the nitrogen-containing steroidal alkaloid, solanidine. 2D NMR characterization by HMBC, COSY, TOCSY, and HSQC-TOCSY proved to be invaluable in the structural elucidation of M1; derivatization of M1 revealed the presence of two carboxylic acid moieties. M1 was determined to be a steroidal alkaloid with a solanidine backbone that had undergone C-C bond scission to yield 3,4-seco-solanidine-3,4-dioic acid (SSDA). SSDA may have value as a dietary biomarker of CYP2D6 activity in populations where potato consumption is common.
Significance statement

Endogenous or dietary biomarkers of processes involved in drug disposition and response may allow improved individualization of drug treatment, especially in vulnerable populations, such as children. Given that several CYP2D6 substrates are commonly used in pediatrics and the ubiquitous nature of potato consumption in Western diets, SSDA has considerable appeal as a non-invasive biomarker of CYP2D6 activity to guide treatment with CYP2D6 substrates in children and adults.
Introduction

One goal of precision therapeutics is to individualize drug doses for patients based on their unique characteristics, thereby optimizing safety and efficacy. The cytochrome P450 2D6 (CYP2D6) enzyme is responsible for metabolizing up to 25% of clinically used drugs (Zhou, 2009a; Zhou, 2009b). CYP2D6 is highly polymorphic with more than 120 allelic variants identified and classified by the Pharmacogene Variation Consortium (PharmVar) at https://www.pharmvar.org/gene/CYP2D6 (Gaedigk et al., 2008). Inheritance of two recessive loss-of-function alleles results in a “poor-metabolizer (PM) phenotype”, whereas combinations of full- or reduced-function alleles result in a wide spectrum of phenotypes including intermediate (IM), extensive (EM), and ultra-rapid metabolizers (UM). As a result, significant inter-individual variability in CYP2D6 phenotype has been observed across multiple patient populations, including within groups of nominally the same genotype (Gaedigk et al., 2008; Jones et al., 2010; Llerena et al., 2012; Brown et al., 2016). Given that phenotype prediction from genotype data can be confounded by environmental factors, such as drug-drug interactions, direct assessment of CYP2D6 phenotype may offer a more accurate assessment of CYP2D6 activity at a given point in time relative to genotyping (Wu, 2011; Kantae et al., 2017).

Traditional phenotyping studies require the administration of a probe compound that is a substrate of the drug metabolizing enzyme of interest, collection of urine for a defined period of time followed by determination of the molar ratio of parent compound and metabolite (Streetman et al., 2000). The over-the-counter cough suppressant, dextromethorphan, is a relatively safe probe for assessment of CYP2D6 phenotype in vivo, and the molar ratio of dextromethorphan to dextrorphan in a 4-hour urine collection has been used to phenotype CYP2D6 activity in infants (Blake et al., 2007), children (Evans et al., 1989), pregnant women (Wadelius et al., 1997; Tracy et al., 2005), and adults (Gaedigk et al., 2008). Although widely used as a phenotyping probe, the dextromethorphan/dextrorphan metabolite ratio can be influenced by factors like urinary pH.
(Labbe et al., 2000), confounding the genotype-phenotype relationship. Other commonly used phenotyping probes, such as debrisoquine, sparteine, and bufurolol, are logistically more difficult to use due to prescription status or are not approved for clinical use in the United States. Thus, there is considerable appeal for biomarkers reflecting CYP2D6 activity that do not require administration of a drug or other exogenous compound.

Several endogenous compounds have been identified as CYP2D6 substrates (Yu et al., 2003a; Yu et al., 2003b), but none has been explored as a potential phenotyping probe. In contrast, our collaborators applied an untargeted, global metabolomics approach using urine collections from patients previously genotyped and phenotyped for CYP2D6 activity with dextromethorphan to identify an “endogenous” biomarker of CYP2D6 activity (Tay-Sontheimer et al., 2014). This effort identified a compound with parent ion mass of m/z 444.3102 (designated M1) and product ions m/z 98.0964, 370.2731, 206.1883, 56.0494, 55.0550 and 81.0692 (in order of decreasing abundance) that were absent in urine from CYP2D6 PMs. M1 was further validated as a product of CYP2D6 activity by observing a decrease in its formation following inhibition of CYP2D6 activity with fluoxetine, a potent CYP2D6 inhibitor. Queries in the common metabolomic databases for the identity of M1 and product ions resulted in no matches, and no further details about the identity of M1 were provided, precluding any further assessment of its clinical utility as a biomarker of CYP2D6 activity.

The goal of this project was to isolate, purify and elucidate the structure of M1. Through a series of chromatographic methods, 1D and 2D NMR experiments and derivatization reactions, we describe the purification and structural identification of a metabolic product of the nitrogen-containing steroidal alkaloid, solanidine, 3,4-seco-solanidine-3,4-dioic-acid (SSDA), as a potential biomarker CYP2D6 activity.
Materials and methods

Materials and reagents. LC-MS Optima grade methanol and acetonitrile were purchased from Thermo Fisher Scientific (Waltham, MA). House water was purified using BARNSTEAD E-pure® 4-model system (Thermo Fisher Scientific, Waltham, MA) to produce 18.1 megohm-cm water and used without further purification. LC-MS grade formic acid, trimethylamine (NEt₃), ethanolamine, ammonium hydroxide solution (28.0-30.0% NH₃), acetic acid, sodium acetate (NaOAc), ammonium acetate (NH₄OAc), ammonium bicarbonate [(NH₄)(HCO₃)], spherical C18 flash silica (45-75 μm, 70 Å), Syringe Loading injection Rheodyne Model 7125 and Supelclean LC-SCX SPE tubes 3 mL were obtained from Millipore-Sigma (St. Louis, MO). 10 cm Omnifit chromatography column was purchased from Diba Industries (msscientific Chromatographie-Handel, Berlin, Germany). Waters SunFire C18 (100 Å, 5.0 μm, 4.6 x 150 mm) and Acquity UPLC BEH C18 (130 Å, 1.7 μm, 2.1 x 100 mm) columns were purchased from Waters (Milford, MA). Methanol-D4 was purchased from Cambridge Isotope Laboratories, Inc (Tewksbury, MA). Imject EDC mcKLH Spin Kit was purchased from Thermo Fisher Scientific Waltham, MA). A total of 40 L of urine was collected from a single individual, pooled in 4 L aliquots with the pH adjusted of each pooled aliquot to pH = 4.0-4.5 using acetic acid. The collection of urine for unknown compound purification was declared non-human subjects research by Children’s Mercy Kansas City Pediatric Institutional Review Board under 45 CFR 46.102(f) (not involving human subjects).

Chromatographic purification of M1. A comprehensive series of preparative procedures were conducted to isolate and purify M1 for subsequent identification. Briefly, these steps included an initial purification using a 10 cm Omnifit C18 flash silica column, a 3 mL Supelclean LC-SCX solid phase extraction cartridge, a second 10 cm Omnifit C18 flash silica column purification step followed by purification using a Waters C18 Sunfire column purification, and a final purification procedure using a Waters Acquity UPLC BEH C18 column. The various steps and
procedures are summarized in Table 1, and a complete description can be found in the Supplementary Methods.

**Chromatography and mass spectrometry.** Fractions collected during preparative chromatography were analyzed on a Waters TQ-XS triple quadrupole step-wave mass spectrometer (Waters, Manchester, UK) that was connected to an I-Class Acquity UPLC with a flow-through needle (FTN) sample manager. The instrument was operated in ESI+ mode. The probe capillary was optimized at 3.0 kV and desolvation temperature was set to 400 °C. The source offset was set to 60 V. The following gas flows were used: desolvation gas, 800 L/hr; collision gas flow, 0.15 mL/min; and nebulizer, 7.0 bar. Argon was used for collision-induced dissociation (CID). Analytes were separated on a Waters Acquity UPLC C18 reversed-phase column (BEH 1.7 μm, 2.1 x 50 mm) that was preceded by a Waters Acquity UPLC C18 VanGuard Precolumn (1.7 μm, 2.1 x 5 mm). The following gradient was used on the UPLC system: initial conditions of 1% B, increasing linearly to 99% B at 4.0 min and held for 1 min. At 5.10 min, the column was stepped down to initial conditions. Mobile phases A and B were H2O and MeOH, respectively, both containing 0.1% formic acid. The flow rate was 0.4 mL/min and column temperature was set to 25 °C.

**Nuclear magnetic resonance (NMR) conditions.** NMR samples were prepared by dissolving the compound in approximately 500 or 300 μL of CD3OD (Cambridge Isotopes, Tewksbury, MA), then transferring to a 5 mm conventional tube (Wilmad LabGlass, Vineland, NJ) or Shigemi tube (Shigemi Co. LTD., Tokyo, Japan), respectively. All NMR spectra were acquired using a Bruker AVIII 500 MHz spectrometer equipped with a cryogenically cooled broadband observe probe or 800 MHz Bruker AV spectrometer equipped with a cryogenically cooled triple resonance inverse probe. NMR experiments were acquired and processed using Bruker Topspin and MestreNova software, respectively, with conventional parameters, unless otherwise noted. 1H NMR shifts given were referenced internally to residual protonated solvent resonance at δ 3.31 ppm.
(CD$_2$HOD). $^{13}$C NMR shifts given were referenced internally to solvent resonance at $\delta$ 49.0 ppm (CD$_3$OD). All values in parentheses are coupling constants (Hz) where $^2J$ and $^3J$ denote germinal and vicinal couplings, respectively.

**Derivatization of SSDA.** A 2 mL glass auto sample vial was charged with 10 $\mu$L of a 1:1000 diluted solution of purified unknown M1 and evaporated to dryness, and redissolved with 1 mL of Imject EDC conjugation Buffer. 10 $\mu$L of a 1M ethanolamine solution was added to the solution and [H$^+$] was checked to ensure pH = 5. 1-ethyl-3-(2-dimethylaminopropyl) carbodiimide HCl (EDC, 10 mg, 0.522 mmol) was added to the solution and vortexed. The mixture was placed in a 60 °C oven. Reaction progress was analyzed by pulling 20 $\mu$L samples at time interval of 30, 60, 90, and 240 minutes and diluted to final volume of 200 $\mu$L of using 90:10 10 mM NH$_4$OAc buffer, pH = 7.0/MeOH solution. Samples were analyzed on Xevo G2-XS QToF mass spectrometer (Waters, Manchester, UK) that was connected to a M-Class Acquity UPLC with a flow-through needle (FTN) sample manager (complete details of the chromatography conditions are provided in the **Supplemental Methods**).

**Results**

**Elemental composition by high resolution mass spectrometry.** Using high resolution mass spectrometry, the monoisotopic mass $(M+H)^+$ of M1 was determined to be 444.3115 Da, and based on this information, the isotopic distribution, and the nitrogen rule, an elemental composition of C$_{27}$H$_{41}$NO$_4$ was proposed. This elemental composition deviated from the theoretical value of 444.3114 by 0.1 mDa (0.2 ppm) and matched the predicted isotopic pattern (I-Fit confidence of 99.52%). The double bond equivalent (DBE) of this elemental composition was 8. Querying the elemental composition against major databases yielded no identification, as previously reported (Tay-Sontheimer et al., 2014), and a relatively high collision energy (50
eV) was required to fragment M1 into the previously reported fragments. We performed a search of the fragments against the HMDB database (using an in-house developed tool) and found that the fragment at 98.0964, and the couplet of 204.1743 and 206.1906 matched the in-silico generated fragmentation pattern of the steroidal alkaloid solanidine. A literature search revealed that the low molecular weight CID fragments of M1 have been commonly observed in various steroidal alkaloids (Cahill et al., 2010; Zhou et al., 2010); however, the 444.3→370.3 transition, a loss of 74 Da, is unique for this molecule and could not be adequately explained. A search of the steroidal alkaloidal literature for a better match than a solandine-derived structure was unsuccessful, and due to the limited utility of CID spectra for de-novo identification of steroidal alkaloids, the decision was made to isolate the compound.

**Isolation of M1 from human urine.** Comparison of peak areas between a known concentration of solanidine and an unknown concentration of M1 resulted in an estimated M1 concentration of 20 nM or 8.9 μg/L in human urine. Based on NMR sensitivity considerations (e.g., https://www.chem.wisc.edu/~cic/nmr/Guides/Other/sensitivity-NMR.pdf) we estimated that approximately 100-300 μg of M1 would be required to obtain an interpretable \(^{13}\)C\{\(^{1}\)H\}\ NMR spectrum (Fig S15). Therefore, M1 isolation and purification was initiated using 40 L of human urine, using the series of chromatographic steps described in **Methods**. The challenges associated with each step and the approaches taken to resolve those issues are described in more detail in **Supplemental Results**. The final product of the isolation and purification process was a solution that appeared pure by qTOF mass spectrometry and served as the source material for interrogation by NMR and determination of M1 structure.

**NMR analysis of M1.** Multiple NMR experiments were performed to characterize purified M1, including \(^{1}\)H, \(^{13}\)C\{\(^{1}\)H\}\, DEPT135\(^{13}\)C\{\(^{1}\)H\}\, DEPT90\(^{13}\)C\{\(^{1}\)H\}\, HSQC, HMBC, COSY, 2D TOCSY, and HSQC-TOCSY; raw spectra are provided in the Supplementary Material (Fig. S1-S37). The interpreted NMR spectra are summarized in **Table 2** and **Table 3**.

11
$^{13}$C{$^{1}$H}, DEPT135-$^{13}$C{$^{1}$H} and DEPT90-$^{13}$C{$^{1}$H} (Fig. S12-15) experiments confirmed the elemental composition of M1 and documented the presence of twenty-seven unique carbons, including four methyl (CH$_3$), nine methylene (CH$_2$), nine methine (CH), and five quaternary (C) carbons. The $^1$H NMR experiment showed 39 protons, two less than the proposed elemental composition; however, exchangeable protons are not observed in $^1$H NMR experiments acquired in protic solvents (e.g. CD$_3$OD).

$^1$H and $^{13}$C{$^{1}$H} NMR spectra of solanidine in CD$_3$OD were prepared so that the NMR spectra of M1 could be compared against that of solanidine (Fig. S1 and Table 2). Solanidine contains several structural features that result in diagnostic signals in $^1$H and $^{13}$C{$^{1}$H} NMR experiments due to 1) the 4 methyl groups, 2) the heterocyclic structure (due to the nitrogen), 3) the unsaturation in the B-ring, and 4) the single hydroxyl group. Analogous to solanidine, four methyl groups were observed for M1, and the splitting patterns of the four methyl groups (C-18, C-19, C-21, and C-27) matched the expected pattern of singlet, singlet, doublet and doublet, for each methyl group respectively. Zooming in on the aliphatic region of the $^1$H NMR spectrum (Fig. S2) of M1 highlights the chemical resonances of four methyl groups (Fig. S3). Additionally $^{13}$C{$^{1}$H} chemicals shifts of the carbons adjacent to the nitrogen (C-16, C-17, and C-22) are highly characteristic for solanidine and have values of 71.1, 62.9 and 76.3 ppm for M1 (Table 2). The unsaturation in the B-ring of solanidine on C5 and C6 could also be observed in M1, although C6 resonated 13.6 ppm downfield in M1, relative to solanidine (135.9 vs. 122.3 ppm). Interestingly the last diagnostic signal in solanidine, is related to the hydroxyl group on carbon 3, which was not observed in M1.

Stepwise connectivity models used to identify M1 as SSDA are summarized in Figure 1. Our strategy hinged on using the HSQC, HMBC, 2D TOCSY and HSQC-TOCSY experiments to build these connectivity models, which were initiated at resonances that were separated from the overlapping aliphatic regions of the spectra, namely methyl groups and the olefin. We
started with the resonance at 1.27 ppm in the $^1$H NMR spectrum. In the HMBC experiment this proton (C19-H) displayed correlations with four carbon atoms, C-5, C-9, C-10, and ambiguous cross peak with either C-1, C-2, C-7, or C-24. C-10 and C-5 are both quaternary carbons because they had no correlations in the HSQC experiment. Given the chemical shift of C-5 ($\delta$ 142.2), it is highly suggestive that it is a sp$^2$-hybridized carbon. Likewise, in the HMBC experiment C6-H displayed correlations with C-8, C-10, C-4, and ambiguous correlation with either C-1, C-2, C-7, or C-24. The $^1$H and $^{13}$C($^1$H) chemical shifts of C-6 suggest it is an olefin group (-HC=). The resonance assigned to C4 has a chemical shift of 174.1 ppm implying the presence of a carbonyl moiety. C6-H in M1 is significantly shifted downfield from that of solanidine (Table 2) suggesting the presence of an electron withdrawing group near C6-H. Finally, the C3-H of solanidine is missing in the $^1$H spectrum of M1 indicating possible structural modification of the A-ring.

The HSQC-TOCSY experiment revealed that C6-H had correlations with only C8-H, and ambiguous correlations with either C-1, C-2, C-7, or C-24 further supported the assignment of C-6 as adjacent to a quaternary carbon, C-5 (Figure 1A). Analysis of the 2D COSY spectrum revealed correlation of C6-H with C7-H' (Fig. S30). C-7 contained diastereotopic protons (H', $\delta$ 2.17) and (H, $\delta$ 1.73-1.69, Table 2). C7-H' had correlations with C-5, C-6, C-8, C-9, and C-14 in the HMBC experiment. The HSQC-TOSCY C7-H' showed only cross peaks with C-6 and C-8. Unfortunately, C7-H overlapped with C2-H and C8-H proton resonances. The HMBC experiment for C8-H had cross peaks with C-5, C-6, C-9, C-14, and C-19. Incorporation of this information expanded the stepwise connectivity model to include C-8, C-9, and C-14 (Figure 1B).

HSQC data revealed that C-2 contained diastereotopic protons, C2-H' ($\delta$ 2.33) and C2-H ($\delta$ 1.79-1.71), and the HMBC experiment demonstrated that C2-H' had correlations with C-3, C-9, C-10, C-19, where C-3 had a chemical shift of 181.5 ppm suggesting it could be a carbonyl
The HSQC-TOCSY experiment showed a single correlation that could not be resolved unambiguously, however, the observation of only one correlation in the HSQC-TOCSY implies that C-2 is adjacent to at least one quaternary carbon. Since the C2-H' resonance at 2.33 ppm was well separated, we could use the 2D TOCSY experiment to determine that this resonance is coupled with diastereotopic protons at $\delta$ 2.07 and $\delta$ 2.03-1.99 ppm, along with geminal coupling with C2-H at $\delta$ 1.79-1.71 (Fig. S6-7). Resonances C1-H and C15-H' ($\delta$ 2.03-1.99) are overlapped with each other (Fig. S6-7). Both C-1 and C-15 have diastereotopic protons, C1-H' ($\delta$ 2.07) and C1-H ($\delta$ 2.03-1.99) and C15-H' ($\delta$ 2.03-1.99) and C15-H ($\delta$ 1.32-1.29). Since C2-H' did not have a correlation with C15-H in the TOCSY experiment, the correlation at $\delta$ 2.07 and $\delta$ 2.03-1.99 represents C1-H' and C1-H, respectively (Fig. S6-7). This is further supported by the HMBC experimental results wherein C1-H' had correlations with C-3, C-10 and ambiguous cross peaks with C-2, C-7 or C-24. The TOCSY for C1-H'/C15-H and C1-H also had only two correlations, C2-H' ($\delta$ 2.33) and C2-H ($\delta$ 1.79), indicating it was also adjacent a quaternary carbon (Fig. S7). We also noted there was no correlation between C15-H and C2-H' in the 2D TOCSY (Fig. S32). With these results the stepwise connectivity model was broadened to include C-1 through C-3 (Figure 1C).

The HSQC experiment revealed C-11 to have diastereotopic protons, C11-H' ($\delta$ 1.66, dd, $^2J_{\text{H-H}} = 13.0\text{ Hz}, \ ^3J_{\text{H-H}} = 3.8\text{ Hz}$) and C11-H ($\delta$ 1.54, qd, $^2J_{\text{H-H}} = 13.0\text{ Hz}, \ ^3J_{\text{H-H}} = 3.8\text{ Hz}$). The HMBC experiment showed C11-H' correlations to C-9 and C-12. C-12 has diastereotopic protons C12-H' ($\delta$ 1.88-1.78) and C12-H ($\delta$ 1.34-1.28). Focusing on the other methyl resonance that is a singlet, C18-H ($\delta$ 0.90), the HMBC experiment revealed that C18-H correlates to C-12, C-13, C-14, C-17, and C-20. HSQC-TOCSY demonstrated that C18-H had no correlations because it was adjacent to a quaternary carbon, C-13. The HMBC experiment for C14-H revealed correlations to C-8, C-13, C-14, C-16, C-17, and C-18, and C-11, C-12, C-13, C-16, C-17, C-18 and C-20 could now be added to the connectivity model (Figure 1D).
D-ring assignment. The third methyl group ($\delta$ 1.03 ppm, d, $^3J_{CH} = 6.2$ Hz), which is a doublet and hence must be adjacent to a carbon with only one unique hydrogen, making it a methine (-CH) carbon, is assigned to C21-H. The HMBC for C21-H had correlations to C-17, C-20, and C-22. The HSQC-TOCSY for C21-H showed correlations to C-16, C-17, C-20, C-22, C-23, and ambiguous cross peaks to C-1, C-2, C-7, or C-24 (Table 3). Unfortunately, C22-H had no correlations in the HMBC and HSQC-TOCSY experiments. We examined the COSY experiment for C21-H to see if any correlations could be found. C21-H correlated to one multiplet ($\delta$ 1.88-1.79) that represented overlapped resonances from C12-H', C17-H, C20-H, C24-H', and C25-H. Given the downfield shift of the C-16 ($\delta = 71.1$ ppm; Table 2), we reasoned that C-16 is adjacent to an electronegative atom. C-16 in solanidine has a resonance at $\delta$ 70.9 ppm and can explain the downfield shift due to the presence of the tertiary alkylamine. In the M1 $^1$H NMR spectrum C16-H and C26-H are overlapped ($\delta$ 3.26-3.20). The HMBC experiments for C16-H and C26-H showed no correlations; however, the HSQC-TOCSY displayed correlations with C-15, C-25, C-26, C-27 and ambiguous cross peaks to either C-1, C-2, C-7, or C-24. Based on the DEPT90 and DEPT135 experiments, C-16 is a methine carbon and C-26 is a methylene. The 2D TOCSY experiment of C16-H had correlations with C15-H' ($\delta$ 2.03-1.99) and C21-H. C16-H also had correlations with overlapped two regions $\delta$ 1.88-1.80 ppm (C12-H', C17-H, C20-H, C24-H' and C25-H) and $\delta$ 1.32-1.29 ppm (C9-H, C12-H, C14-H and C15-H). The COSY experiment for C16-H had two correlations with C15-H' and overlapped resonances of C12-H', C17-H, C20-H, C24-H and C25-H. There are two points of interest here. First, both HSQC-TOCSY experiments for C14-H and C16-H had correlations with C15 and C17. Second, the COSY for C16-H had correlations with C15-H' and C17-H, whereas the 2D TOCSY for C16-H had correlations with C14-H, C15-H', and C17-H. One drawback to an HMBC experiment is that pulse sequences use a single fixed delay based on the average value of $^nJ_{CH}$ (Reynolds and Enríquez, 2002). Complex molecules such as steroidal-alkaloids have a range of $^nJ_{CH}$ values...
(2–15 Hz) and correlations with $^\text{a}$J$_{\text{CH}}$ values that differ significantly from the average will be filtered. Although C-15 did not have correlations with C16-H or C17-H, the HMBC experiments for C15-H’ (δ 2.03-1.99) had correlations with C-13, C-14, and C-17. Additionally, the HMBC experiments for C15-H (δ 1.32-1.29) had correlations with C-13, C-14, C-16, and C-17, and C-18 (Table 2). Based on these results, the D-ring assignment was completed and included in the stepwise connectivity model (Figure 1E).

Proposed M1 structure. Identification of the remaining carbons was completed by examining the final methyl group, C-27. HMBC experiments for C27-H showed correlations with C-25, C-26, and ambiguous cross peak to either C-1, C-2, C-7, or C-24. Like C-21, C-27 must be directly adjacent to a methine carbon, in this case C-25. C-26 was significantly downfield shifted compared to C-24 ($\Delta = 26.7$ ppm) and is directly bonded to the nitrogen atom. The HSQC-TOCSY experiment of C27-H resulted in correlations with C-23, C-25, C-26, and ambiguous cross peaks to C-1, C-2, C-7, or C-24. Assignment of C-23 was completed using the COSY experiment and was found to have diastereotopic protons, C23-H’ (δ 1.93) and C23-H (δ 1.41-1.34). Analysis of C23-H’ resulted in correlations with C24-H’ (δ 1.83-1.78), the multiplet at δ 1.41-1.34 (geminal coupling), and C24-H (δ 1.08-1.04). The HSQC-TOCSY results for C23-H’ had correlations with C27, C24, C25, and C26. HSQC-TOCSY results for C23-H had correlations with only C-24. The completed connectivity model for M1 is presented in Figure 1F.

Heteroatom identification and final structure of SSDA. For heteroatom identification we reviewed the elemental composition of M1, C$_{27}$H$_{41}$NO$_4$ and noted that the proposed structure in Figure 1F has a molecular formula of C$_{27}$H$_{39}$NO$_2$ and is missing two oxygen atoms and two hydrogen atoms. The total sum of the integration values for the resonances in the $^1$H spectrum had a value of 39. Given that all carbon atoms were identified, the remaining oxygen and hydrogen atoms must be part of the carbonyl moieties at C-3 and C-4. Therefore, we propose that M1
contains two carboxylic acids functional groups and is identified as 3,4-seco-solanidine-3,4-dioic acid (SSDA; Figure 2).

**Confirmation of SSDA dicarboxylic structure.** Orthogonal confirmation of the carboxylic acid moieties was acquired by activating the carboxylate groups with carbodiimide followed by reaction with ethanolamine (Fig. S32). Reaction progress was monitored using mass spectrometry. The first amidation reaction was facile, with the disappearance of the parent ion of m/z 444.31 and appearance of m/z 487.35, indicating the addition of 1 unit of ethanolamine. The second amidation required an increase in temperature to 60˚C and was confirmed with the appearance of the m/z 530.39(Fig. S38 and S39), consistent with the proposed SSDA structure.

**Determination of parent and product ion structures.** Support for the proposed structure of SSDA is further corroborated by the product ion assignments from the MS/MS fragmentation experiment (Figure 3). Collision induced dissociation (CID) of the parent ion of m/z 444.3123 resulted in six major product ions: m/z 370.2744, m/z 356.2582, m/z 326.2851, m/z 206.1908, m/z 150.1270, m/z 136.1116, and m/z 98.0983, and each of the major fragments can now be explained by simple bond breaking. The product ion of m/z 370.2744 had a mass loss of m/z 74.0379 with an elemental composition of C₃H₆O₂. This fragmentation represents the loss of the propionic acid chain. The product ion of m/z 356.2582 had an elemental composition of C₂₃H₃₆NO₂ and represents a mass loss of m/z 88.0541 from the parent ion, which would be consistent with propionic acid and a methyl group. The product ion 326.2851 m/z had an elemental composition of C₂₃H₃₆N. The mass loss difference between product ions m/z 370.2744 and m/z 326.2851 of 43.9893 represents loss of CO₂, or the second carboxylic acid moiety. The product ion of m/z 206.1908 had an elemental composition of C₁₄H₂₄N and represents the loss of B and C rings. The product ion m/z of 150.1270 had an elemental composition of C₁₀H₁₆N and can be described as the fragment composed of a hydro-indolizine ring, a diagnostic feature of solanidine-based alkaloids (Lawson et al., 1997; Shou et al., 2010).
The product ion of m/z 98.0983 had an elemental composition of C₆H₁₂N and is described as the six-member amino-alkane ring.

Quantitative NMR was performed using an internal calibrant, and a quantity of 96 μg of SSDA was determined with a purity of 99.8% with the assumption that salts and other inert NMR impurities have been removed from the overall purification methods (Tables S1-S3).

**Discussion**

In this investigation we report the structure of an “endogenous” biomarker of CYP2D6 previously discovered by an untargeted, global metabolomics approach using urine collections from patients previously genotyped and phenotyped for CYP2D6 activity with dextromethorphan (Tay-Sontheimer et al., 2014). The compound, designated “M1” was characterized by a parent ion mass of m/z 444.3102, was absent in urine of CYP2D6 poor metabolizers, and its formation was reduced *in vivo* by co-administration of the CYP2D6 inhibitor, fluoxetine. Present at relatively low concentrations in urine, M1 was isolated and purified from ~40 L of urine and determined to be a metabolite of solanidine, 3,4-seco-solanidine-3,4-dioic acid. As solanidine is a toxic glycoalkaloid produced by members of the Solanaceae family and found at particularly high concentrations in the metabolically active parts of plants, such as leaves, flowers and sprouts of potatoes (Omayio et al., 2016; Saranya et al., 2018), SSDA is dietary in origin and not an “endogenous” biomarker of CYP2D6 activity.

The structure of SSDA was somewhat unusual and unexpected, but the final structure is plausible for several reasons. First, the ¹H NMR experiments were conducted in CD₃OD and acidic protons are known undergo H/D exchange in protic deuterated solvents like methanol. Secondly the ¹³C{¹H} chemical shifts for C-3 and C-4 are δ 181.5 and 174.1, respectively, and
correspond very well to reported chemical shifts of carboxylic acid moieties in C$_{27}$ products. For example, 3,4-seco-12$\alpha$-hydroxy-5$\beta$-cholan-3,4,24-trioic acid, a bile acid produced from cholesterol metabolism, has been synthesized and characterized using NMR techniques (Sekiguchi et al., 2017). Its reported $^{13}$C{$^{1}$H} chemical shifts for C-3 and C-4 are $\delta$ 176.4 and $\delta$ 177.2, respectively. Furthermore, scission of the A-ring is not uncommon. Exploration of the literature reveals that A-ring opening of steroidal compounds is not unprecedented as there are multiple examples that proceed by a mechanism involving oxidation of the alcohol followed by a Baeyer-Villiger oxidation and, subsequently, hydrolysis. For example, trans-cyclohexa-1,2-diol has been reported to be oxidized to the dicarboxylic acid adipate by the fungus Acinetobacter TD63 via a mechanism that involves an initial dehydrogenation to 2-hydroxycyclohexane-1-one, ring expansion to form a lactone, 1-oxa-2-oxo-7-hydroxycycloheptane, rearrangement to 6-oxohexanoate, and subsequently adipate (Davey and Trudgill, 1977). Similarly, 3$\beta$-acetoxy-5$\alpha$-androstan-3-one is reported to undergo A-ring opening when incubated in the presence of Myceliophthora thermophile (Hunter et al., 2009), and the A-ring of testosterone can be cleaved under anaerobic conditions by Steroidobacter denitrificans (Wang et al., 2013). Perhaps of most relevance to SSDA formation, the structurally similar steroidal alkaloid, tomatidine, has been shown to undergo degradation via A-ring opening to form 4-hydroxy-3,4-seco-tomatidine-3-oic acid in the presence of the fungus, Gymnoascus reesii (Gaberc-Porekar et al., 1983).

There are also several reports describing a role for mammalian oxidative enzymes catalyzing Baeyer-Villiger oxidation of steroidal substrates (Leisch et al., 2011). Verhoeven and co-workers reported A-ring opening of a progestogen, (17$\alpha$)-17-hydroxy-11-methylene-19-norpregna-4,15-dien-20-yn-3-one, was the major metabolic route after oral administration of the compound to rats (Verhoeven et al., 1998), and Lai et al (Lai et al., 2011) reported on the oxidation and opening of a keto-piperidine group of a poly(ADP-ribose) polymerase inhibitor; in the latter study, in vitro experiments revealed FMO5 to be responsible for the ring-opening via
Baeyer-Villiger oxidation. Finally, a novel secondary bile acid in the common ring tail possum was recently described and mimics the exact A-ring opening that we observed (Sekiguchi et al., 2017). A-ring scission through a Baeyer-Villiger mechanism and oxidation of the resulting alcohol (following hydrolysis) to the carboxylate is a multistep process.

Given that minimal to no formation of SSDA is observed in CYP2D6 poor metabolizers and that formation is reduced in the presence of CYP2D6 inhibitors in vivo, it is likely that CYP2D6 catalyzes the rate-limiting step in SSDA formation. In fact, incubation of solanidine with heterologously expressed CYP2D6 produced a hydroxylated metabolite that has been identified as 4-hydroxysolanidine by an NMR analysis approach analogous to that described for SSDA (manuscript in preparation), a significant finding in that 3-keto-4-hydroxy compounds are potential substrates for Baeyer-Villiger oxidations as discussed above. Based on the reported trans-cyclohexa-1,2-diol to adipate pathway ((Davey and Trudgill, 1977); Figure 4A) and the reports of 3,4-seco-12α-hydroxy-5β-cholan-3,4,24-trioic acid formed from a secondary bile acid ((Sekiguchi et al., 2017); Figure 4B) and 4-hydroxy-3,4-seco-tomatidine-3-oic acid from tomatidine ((Gaberc-Porekar et al., 1983); Figure 4C), we propose a pathway for formation of SSDA from solanidine following CYP2D6-mediated formation of 4-hydroxysolanidine in Figure 4D. Consistent with this pathway we have also observed structures consistent with dehydrogenation of 4-hydroxysolanidine to form 4-keto-solanidine and 3-keto-4-hydroxysolanidine in patient urine samples, although the enzymes involved in the processes have not yet been identified (manuscript in preparation).

In summary, we have presented the isolation and structural elucidation of SSDA using supporting data from several 1D and 2D NMR experiments, functional group modification reactions and mass spectrometry data. Collectively, the data all support the proposed structure for SSDA and increase confidence in the final assignments. Derived from solanidine, a steroidal alkaloid naturally occurring in plants of the Solanaceae family, such as potatoes, a urinary
metabolite ratio of solanidine/SSDA would be analogous to the dextromethorphan/dextrorphan ratio used to assess CYP2D6 phenotyping following administration of cough suppressant, dextromethorphan. Indeed, during preparation of this manuscript, Magliocco et al. applied an elegant pharmacometabolomic approach to provide compelling evidence for solanidine-based metabolite ratios in urine and plasma as biomarkers of CYP2D6 activity in vivo (Magliocco et al., 2021). Identification of m/z 444.3102 as SSDA and the proposed pathway presented in Figure 4D provides insight into the identities for the major CYP2D6 metabolites m/z 414.3366 and m/z 412.3210 reported in that study. Given that potatoes or potato-derived products are relatively common in North American and European diets, and the relatively long half-life of solanidine (t_{1/2} = 5 days; (Harvey et al., 1985)), we concur with Magliocco et al (Magliocco et al., 2021) that solanidine-based metabolite ratios may have broad utility as a measure of CYP2D6 activity that does not require exogenous drug administration. Clearly, multiple metabolic steps are involved in the biotransformation of solanidine to form SSDA and it is possible that a ratio of solanidine to various combinations of metabolites along the path from 4-hydroxysolanidine to SSDA may ultimately prove superior to administration of an exogenous compound, such as dextromethorphan, as a convenient biomarker of CYP2D6 activity for application in precision therapeutic settings.
Authorship Contributions

Participated in research design: Behrle, Leeder, van Haandel

Conducted experiments: Behrle, Douglas, van Haandel

Performed data analysis and interpretation: Behrle, Douglas, van Haandel

Wrote or contributed to the writing of the manuscript: Behrle, Douglas, Leeder, van Haandel
References


Zhou S-F (2009a) Polymorphism of human cytochrome P450 2D6 and its clinical significance:


Zhou S-F (2009b) Polymorphism of human cytochrome P450 2D6 and its clinical significance:

Footnotes

The longitudinal CYP2D6 phenotyping study in which SSDA was discovered and originally described as an “endogenous” biomarker of CYP2D6 activity was funded by R01 HD058556, Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics (Leeder and Lin, co-PIs). Isolation, purification and identification of M1 as SSDA was supported by internal funding, Children’s Mercy Kansas City (van Haandel, PI). Support for the 500 MHz NMR was provided by NIH Shared Instrumentation Grant # S10RR024664 and NSF Major Research Instrumentation Grant # 1625923. The 800 MHz instrument is supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P30 GM1110761.

No author has an actual or perceived conflict of interest with the contents of this article.


1 Current affiliation: Department of Bioanalytical Chemistry, Charles River Laboratories, Mattawan, MI 49071 (andrew.behrle@crl.com). All work on this project by Dr. Behrle was completed while he was an employee of Children’s Mercy Kansas City.

2 Current affiliation: Analytical Research and Development, NCE Project Team, Abbvie, North Chicago, IL 60064 (leon.vanhaandel@abbvie.com). All work on this project by Dr. van Haandel was completed while he was an employee of Children’s Mercy Kansas City.
Legends to Figures

Figure 1. Stepwise connectivity models of SSDA structure as described in Results with hydrogen atoms omitted for clarity. A. Z = ambiguous assignment of C-1, C-2 and C-24. X = C or heteroatom; B. Z = ambiguous assignment of carbons 1, 2, 24. X = C or heteroatom; C. X = C or heteroatom; D. X = C or heteroatom; E. X = C or heteroatom; R = C or heteroatom; R' = C or heteroatom; (F) X = heteroatom.

Figure 2. Structures of solanidine (A) and final proposed structure of M1 as 3,4-seco-solanidine-3,4-dioic acid (SSDA; B). For solanidine rings are labeled with letters and carbon atoms are numbered; hydrogen atoms omitted for clarity. For SSDA, the numbering of carbon atoms has been omitted for clarity, except for A-ring carbons.

Figure 3. MS/MS fragmentation chromatogram of SSDA (panel A), with labeled product ions. The MS/MS fragmentation chromatogram for the parent compound, solanidine, is provided for reference (panel B).

Figure 4. Proposed pathway for SSDA formation involving Baeyer-Villiger chemistry based on literature precedents. A. Proposed pathway for adipic acid formation from trans-cyclohexa-1,2-diol (Davey and Trudgill, 1977); B. A-ring opening to form 3,4-seco-12α-hydroxy-5β-cholan-3,4,24-trioic acid formed from deoxycholic acid (Sekiguchi et al., 2017); C. Formation of 4-hydroxy-3,4-seco-tomatidine-3-oic acid from tomatidine (Gaberc-Porekar et al., 1983); D. Proposed pathway for formation of 3,4-seco-solanidine-3,4-dioic acid following an initial CYP2D6-mediated hydroxylation to form 4-hydroxysolanidine.
Table 1. Analytical methods used in the isolation and purification of M1 from human urine

<table>
<thead>
<tr>
<th>Starting Urine Volume (L)</th>
<th>Analytical Media</th>
<th>Compounds Removed</th>
<th>Elution Conditions</th>
<th>Final Volume (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>C18 spherical flash (45-75 μm, 70 Å)</td>
<td>Salts and very hydrophobic compounds</td>
<td>50:50 MeOH/H₂O w/ 0.1% acetic acid, pH = 4.4</td>
<td>500</td>
</tr>
<tr>
<td>0.5</td>
<td>3 mL Supelclean LC-SCX SPE cartridge</td>
<td>Neutrals and acids</td>
<td>50:50 MeOH/NH₄OH 2-3% NH₃ solution</td>
<td>150</td>
</tr>
<tr>
<td>0.150</td>
<td>C18 spherical flash (45-75 μm, 70 Å)</td>
<td>Hydrophobic compounds that accumulated on the Sunfire column 95:5 H₂O/MeOH (0.1% NEt₃, 0.1% acetic acid); 80:20; 60:40; 45:55</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sunfire C18 column (5.0 μm, 4.6 x 150 mm)</td>
<td>Hydrophobic compounds</td>
<td>H₂O w/ 0.1% formic acid</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Acquity UPLC BEH C18 column (1.7 μm, 2.1 x 100 mm)</td>
<td>Hydrophobic compounds</td>
<td>90:10 10 mM (NH₄)(HCO₃) buffer, pH = 10/MeOH product 99.8% pure)</td>
<td>1 (444.3115) MeOH</td>
</tr>
</tbody>
</table>
Table 2. $^1$H and $^{13}$C($^1$H) Data for M1 and Solanidine

<table>
<thead>
<tr>
<th>Carbon</th>
<th>M1</th>
<th>Solanidine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$^1$H NMR (δ)$^a$</td>
<td>$^{13}$C($^1$H) NMR (δ)$^a$</td>
</tr>
<tr>
<td>1*</td>
<td>2.07 (td, $^2$J$<em>{HH}$ = 15.0 Hz, $^3$J$</em>{HH}$ = 5.1 Hz) 2.03-1.99 (m)</td>
<td>33.21</td>
</tr>
<tr>
<td>2*</td>
<td>2.33 (td, $^2$J$<em>{HH}$ = 15.0 Hz, $^3$J$</em>{HH}$ = 5.1 Hz) 1.79-1.71 (m)</td>
<td>32.10</td>
</tr>
<tr>
<td>3</td>
<td>Quaternary carbon</td>
<td>181.5</td>
</tr>
<tr>
<td>4</td>
<td>Quaternary carbon</td>
<td>174.1</td>
</tr>
<tr>
<td>5</td>
<td>Quaternary carbon</td>
<td>142.3</td>
</tr>
<tr>
<td>6</td>
<td>6.59 (bd, $^3$J$_{HH}$ = 4.9 Hz)</td>
<td>135.9</td>
</tr>
<tr>
<td>7*</td>
<td>2.17 (dd, $^2$J$<em>{HH}$ = 13.0 Hz, $^3$J$</em>{HH}$ = 5.4 Hz) 1.77-1.69 (m)</td>
<td>33.13</td>
</tr>
<tr>
<td>8</td>
<td>1.73-1.69 (m)</td>
<td>32.1</td>
</tr>
<tr>
<td>9</td>
<td>1.34-1.28 (m)</td>
<td>44.4</td>
</tr>
<tr>
<td>10</td>
<td>Quaternary carbon</td>
<td>40.6</td>
</tr>
<tr>
<td>11*</td>
<td>1.66 (dd, $^2$J$<em>{HH}$ = 13.0 Hz, $^3$J$</em>{HH}$ = 3.8 Hz) 1.54 (qd, $^3$J$<em>{HH}$ = 13.0 Hz, $^3$J$</em>{HH}$ = 3.8 Hz)</td>
<td>21.5</td>
</tr>
<tr>
<td>12*</td>
<td>1.88-1.78 (m)</td>
<td>41.0</td>
</tr>
<tr>
<td></td>
<td>1.34-1.28 (m)</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Quaternary carbon</td>
<td>41.3</td>
</tr>
<tr>
<td>14</td>
<td>1.34-1.28 (m)</td>
<td>58.7</td>
</tr>
<tr>
<td>15*</td>
<td>2.03-1.99 (m)</td>
<td>30.5</td>
</tr>
<tr>
<td></td>
<td>1.32-1.29 (m)</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>3.25-3.20 (m)</td>
<td>71.1</td>
</tr>
<tr>
<td></td>
<td>Chemical Shifts</td>
<td>J-H Coupling</td>
</tr>
<tr>
<td>----</td>
<td>-----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>17</td>
<td>1.88-1.78 (m)</td>
<td>62.9</td>
</tr>
<tr>
<td>18</td>
<td>0.90 (s)</td>
<td>16.6</td>
</tr>
<tr>
<td>19</td>
<td>1.27 (s)</td>
<td>23.6</td>
</tr>
<tr>
<td>20</td>
<td>1.88-1.78 (m)</td>
<td>38.1</td>
</tr>
<tr>
<td>21</td>
<td>1.03 (d, J_H-H = 6.2 Hz)</td>
<td>17.3</td>
</tr>
<tr>
<td>22</td>
<td>2.29-2.23 (m)</td>
<td>76.3</td>
</tr>
<tr>
<td>23*</td>
<td>1.93 (d, J_H-H = 13.0 Hz)</td>
<td>28.6</td>
</tr>
<tr>
<td></td>
<td>1.41-1.34 (m)</td>
<td></td>
</tr>
<tr>
<td>24*</td>
<td>1.88-1.78 (m)</td>
<td>33.05</td>
</tr>
<tr>
<td></td>
<td>1.08-1.04 (m)</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>1.83-1.78 (m)</td>
<td>31.2</td>
</tr>
<tr>
<td>26*</td>
<td>3.26-3.20 (m)</td>
<td>60.7</td>
</tr>
<tr>
<td></td>
<td>1.98-1.96 (m)</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>0.94 (d, J_H-H = 6.6 Hz)</td>
<td>19.3</td>
</tr>
</tbody>
</table>

Table key: s (singlet), d (doublet), t (triplet), q (quartet), bd (broad doublet), m (multiplet).

\( ^1H \) (800 MHz) and \( ^13C{\{ ^1H \}} \) (125 MHz) NMR in methanol-\( d_4 \).

\( ^1H \) (500 MHz) and \( ^13C{\{ ^1H \}} \) (125 MHz) NMR in methanol-\( d_4 \).

Carbon resonances overlapped.

Carbon atoms with diastereotopic protons.
Table 3. NMR Data for M1

<table>
<thead>
<tr>
<th>Carbon No.</th>
<th>$^1$H NMR (δ)</th>
<th>$^{13}$C{$^1$H} NMR (δ)</th>
<th>HMBC (carbon numbers)</th>
<th>HSQC-TOCSY (carbon numbers)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2.07 (td, $^2$J$<em>{H-H}$ = 15.0 Hz, $^3$J$</em>{H-H}$ = 5.1 Hz), H'</td>
<td>33.21$^a$</td>
<td>$^a$, 10, 3</td>
<td>$^a$</td>
</tr>
<tr>
<td></td>
<td>2.03-1.99$^b$ (m)</td>
<td>32.85$^a$</td>
<td>$^a$, 13, 14, 17, 3</td>
<td>15, $^a$, 20, 14, 17, 16</td>
</tr>
<tr>
<td>2</td>
<td>2.33 (td, $^2$J$<em>{H-H}$ = 15.0 Hz, $^3$J$</em>{H-H}$ = 5.1 Hz), H'</td>
<td>19, $^a$, 10, 9, 3</td>
<td>$^a$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.79-1.71$^c$ (m), H</td>
<td>19, 8, 14, 6, 5</td>
<td>11, 15, 8, $^a$, 12, 9, 14, 6</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Quaternary carbon</td>
<td>181.5</td>
<td>No cross peaks</td>
<td>No cross peaks</td>
</tr>
<tr>
<td>4</td>
<td>Quaternary carbon</td>
<td>174.1</td>
<td>No cross peaks</td>
<td>No cross peaks</td>
</tr>
<tr>
<td>5</td>
<td>Quaternary carbon</td>
<td>142.3</td>
<td>No cross peaks</td>
<td>No cross peaks</td>
</tr>
<tr>
<td>6</td>
<td>6.59 (bd, $^3$J$_{H-H}$ = 4.9 Hz)</td>
<td>135.9</td>
<td>8, $^a$, 10, 4</td>
<td>8, $^a$</td>
</tr>
<tr>
<td>7</td>
<td>2.17 (dd, $^2$J$<em>{H-H}$ = 13.0 Hz, $^3$J$</em>{H-H}$ = 5.4 Hz), H'</td>
<td>33.13$^a$</td>
<td>8, 9, 14, 5, 6</td>
<td>8, 6</td>
</tr>
<tr>
<td></td>
<td>1.73-1.69$^c$ (m), H</td>
<td>19, 8, 9, 14, 5, 6</td>
<td>11, 15, 8, $^a$, 12, 9, 14, 6</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>1.73-1.69$^c$ (m)</td>
<td>32.1</td>
<td>19, 8, 9, 14, 5, 6</td>
<td>11, 15, 8, $^a$, 12, 9, 14, 6</td>
</tr>
<tr>
<td>9</td>
<td>1.34-1.28$^d$ (m)</td>
<td>44.4</td>
<td>18, 8, 13, 14, 16, 17</td>
<td>11, 15, 8, $^a$, 12, 9, 14, 17, 16</td>
</tr>
<tr>
<td>10</td>
<td>Quaternary carbon</td>
<td>40.6</td>
<td>No cross peaks</td>
<td>No cross peaks</td>
</tr>
<tr>
<td>11</td>
<td>1.66 (dd, $^2$J$<em>{H-H}$ = 13.0 Hz, $^3$J$</em>{H-H}$ = 3.8 Hz), H'</td>
<td>21.5</td>
<td>No cross peaks</td>
<td>11, 12, 9</td>
</tr>
<tr>
<td></td>
<td>1.54 (qd, $^2$J$<em>{H-H}$ = 13.0 Hz, $^3$J$</em>{H-H}$ = 3.8 Hz), H</td>
<td></td>
<td>12, 9</td>
<td>12</td>
</tr>
<tr>
<td>12</td>
<td>1.88-1.78$^e$ (m), H'</td>
<td>41.0</td>
<td>21, 11, $^a$, 13, 9, 14, 22</td>
<td>21, 27, 11, 23, 15, 25, 8, $^a$, 20, 12, 9, 14, 26, 17, 16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>13</td>
<td>Quaternary carbon</td>
<td>41.3</td>
<td>No cross peaks</td>
<td>No cross peaks</td>
</tr>
<tr>
<td>14</td>
<td>1.34-1.28 (m)$^d$</td>
<td>58.7</td>
<td>18, 8, 13, 14, 16, 17</td>
<td>11, 15, 8, $^a$, 12, 9, 14, 17, 16</td>
</tr>
<tr>
<td>15</td>
<td>2.03-1.99$^b$ (m), H'$^a$</td>
<td>30.5</td>
<td>$^a$, 13, 14, 17, 3</td>
<td>15, $^a$, 20, 14, 17, 16</td>
</tr>
<tr>
<td>16</td>
<td>3.25-3.20$^i$ (m)</td>
<td>71.1</td>
<td>No cross peaks</td>
<td>27, 15, 25, $^a$, 26, 16</td>
</tr>
<tr>
<td>17</td>
<td>1.88-1.78$^e$ (m)</td>
<td>62.9</td>
<td>21, 11, $^a$, 13, 9, 14, 22</td>
<td>21, 27, 11, 23, 15, 25, 8, $^a$, 20, 12, 9, 14, 26, 17, 16,</td>
</tr>
<tr>
<td>18</td>
<td>0.90 (s)</td>
<td>16.6</td>
<td>20, 12, 13, 14, 17</td>
<td>No cross peaks</td>
</tr>
<tr>
<td>19</td>
<td>1.27 (s)</td>
<td>23.6</td>
<td>$^a$, 10, 9, 5</td>
<td>No cross peaks</td>
</tr>
<tr>
<td>20</td>
<td>1.88-1.78$^e$ (m)</td>
<td>38.1</td>
<td>21, $^a$, 9, 14, 13, 22</td>
<td>21, 27, 11, 23, 15, 25, 8, $^a$, 20, 12, 9, 14, 26, 17, 16,</td>
</tr>
<tr>
<td>21</td>
<td>1.03 (d, $^3$J$_{H,H} = 6.2$ Hz)</td>
<td>17.3</td>
<td>20, 17, 22</td>
<td>23, $^a$, 20, 17, 16, 22</td>
</tr>
<tr>
<td>22</td>
<td>2.29-2.23 (m)</td>
<td>76.3</td>
<td>No cross peaks</td>
<td>No cross peaks</td>
</tr>
<tr>
<td>23</td>
<td>1.93 (d, $^2$J$_{H,H} = 13.0$ Hz), H'$^a$</td>
<td>28.6</td>
<td>No cross peaks</td>
<td>27, $^a$, 26</td>
</tr>
<tr>
<td>24</td>
<td>1.88-1.78$^e$ (m), H'$^a$</td>
<td>33.05$^a$</td>
<td>21, $^a$, 11, 13, 9, 14, 22</td>
<td>21, 27, 11, 23, 15, 25, 8, $^a$, 20, 12, 9, 14, 26, 17, 16,</td>
</tr>
<tr>
<td>25</td>
<td>1.83-1.78$^e$ (m)</td>
<td>31.2</td>
<td>21, $^a$, 11, 13, 9, 14, 22</td>
<td>21, 27, 11, 23, 15, 25, 8, $^a$, 20, 12, 9, 14, 26, 17, 16,</td>
</tr>
<tr>
<td></td>
<td>3.26-3.20 f (m), H'</td>
<td>No cross peaks</td>
<td>27, 15, 25, a, 26, 16</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---------------------</td>
<td>----------------</td>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>1.98-1.96 (m), H</td>
<td>No cross peaks</td>
<td>no cross peaks</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>0.94 (d, J_H,H = 6.6 Hz)</td>
<td>19.3</td>
<td>23, 25, a, 26</td>
<td></td>
</tr>
</tbody>
</table>

\[ a \text{ Ambiguous assignment of carbons 1, 2, 7, 24.} \]

\[ b \text{ Overlapped proton resonances from carbons 1 and 15.} \]

\[ c \text{ Overlapped proton resonances from carbons 2, 7, and 8.} \]

\[ d \text{ Overlapped proton resonances from carbons 9, 12, 14, and 15.} \]

\[ e \text{ Overlapped proton resonances from carbons 12, 17, 20, 24, and 25.} \]

\[ f \text{ Overlapped proton resonances from carbons 16 and 26.} \]
Figure 2

A

Solanidine

B

3,4-seco-Solanidine-3,4-Dioic Acid
Figure 4

A.  

\[
\text{trans-Cyclohexa-1,2-diol} \quad \rightarrow \quad \text{2-Hydroxycyclohexane-1-one} \quad \rightarrow \quad \text{1-oxa-2-oxo-7-Hydroxycycloheptane} \quad \rightarrow \quad \text{6-Oxohexanoate} \quad \rightarrow \quad \text{Adipic Acid}
\]

B.  

3,4-Seco-12α-hydroxy-5β-cholan-3,4,24-trioic acid

C.  

3-Hydroxy-3,4-seco-tomatidine-3-oic acid

D.  

- **Solanidine**: $C_{27}H_{43}NO$  
  *m/z* 398.3423
- **4-Hydroxysolanidine**: $C_{27}H_{43}NO_2$  
  *m/z* 414.3772
- **3-keto-4-Hydroxysolanidine**: $C_{27}H_{41}NO_2$  
  *m/z* 412.3216
- **SSDA**: $C_{27}H_{41}NO_4$  
  *m/z* 443.3108
Isolation and Identification of 3,4-Seco-Solanidine-3,4-dioic acid (SSDA) as a Urinary Biomarker of Cytochrome P450 2D6 (CYP2D6) Activity

Andrew C Behrle¹, Justin Douglas, J. Steven Leeder and Leon van Haandel²

Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, and Children’s Mercy Research Institute, Children’s Mercy Kansas City, Kansas City MO 64108, USA (A.C.B., J.S.L., L.vH.); Department of Chemistry, University of Kansas, Lawrence, KS 66045, USA (J.D.), and Schools of Medicine and Pharmacy, University of Missouri-Kansas City, Kansas City, MO, 64108, USA (J.S.L.)
Supporting Information Table of Contents

Supplemental Methods

Supplemental Results

Equation S1. Number of double bond equivalents.

Supplemental Figure S1. Enhanced view of $^1$H NMR spectrum of solanidine showing four methyl resonances in CD$_3$OD. Insert showing C6-H ($\delta = 5.45$, $^3$J$_{H-H} = 5.6$ Hz, 1H) and C3-H ($\delta = 3.40$, m, 1H) resonances.

Supplemental Figure S2. $^1$H spectrum of SSDA

Supplemental Figure S3. Enhanced view of $^1$H NMR spectrum of the unknown CYP2D6 biomarker showing four methyl resonances in CD$_3$OD. Insert showing methylidyene resonance.

Supplemental Figure S4. Stepwise connectivity model of unknown CYP2D6 biomarker. a = Ambiguous assignment of C-1, C-2 and C-24. X = C or heteroatom. Hydrogen atoms omitted for clarity.

Supplemental Figure S5. Stepwise connectivity model of unknown CYP2D6 biomarker. a = Ambiguous assignment of carbons 1, 2, 24. X = C or heteroatom. Hydrogen atoms omitted for clarity.

Supplemental Figure S6. 2D TOCSY with enhanced view of C2-H' correlations with C1-H' and/or C15-H'. Red circle represents missing C15-H correlation.

Supplemental Figure S7. 2D TOCSY with enhanced view of C1-H' and C1-H correlations C2-H' and C2-H.

Supplemental Figure S8. Stepwise connectivity model of unknown CYP2D6 biomarker. X = C or heteroatom. Hydrogen atoms omitted for clarity.

Supplemental Figure S9. Stepwise connectivity model of unknown CYP2D6 biomarker. X = C or heteroatom. Hydrogen atoms omitted for clarity.

Supplemental Figure S10. Stepwise connectivity model of unknown CYP2D6 biomarker. X = C or heteroatom; R = C or heteroatom; R' = C or heteroatom. Hydrogen atoms omitted for clarity.

Supplemental Figure S11. Stepwise connectivity model of unknown CYP2D6 biomarker. X = heteroatom. Hydrogen atoms omitted for clarity.

Supplemental Figure S12. $^{13}$C{1H} NMR spectrum of SSDA.

Supplemental Figure S13. Enhanced $^{13}$C{1H} NMR spectrum of SSDA.

Supplemental Figure S14. DEPT135 $^{13}$C{1H} NMR spectrum of SSDA.

Supplemental Figure S15. DEPT90 $^{13}$C{1H} NMR spectrum of SSDA.
Supplemental Figure S16. HSQC full spectrum of SSDA in CD$_3$OD.

Supplemental Figure S17. HSQC enhanced spectrum of SSDA in CD$_3$OD.

Supplemental Figure S18. HMBC spectrum of SSDA in CD$_3$OD.

Supplemental Figure S19. HMBC spectrum of SSDA in CD$_3$OD with C6–H correlations.

Supplemental Figure S20. HMBC enhanced spectrum of SSDA in CD$_3$OD.

Supplemental Figure S21. HMBC enhanced spectrum of SSDA in CD$_3$OD with C18–H, C19–H, C21–H and C27–H correlations.

Supplemental Figure S22. HMBC spectrum of SSDA in CD$_3$OD with long range J filter width = 6 Hz.

Supplemental Figure S23. HMBC enhanced spectrum of SSDA in CD$_3$OD with long range J filter width = 6 Hz.

Supplemental Figure S24. HMBC spectrum of SSDA in CD$_3$OD with long range J filter width = 4 Hz.

Supplemental Figure S25. HMBC enhanced spectrum of SSDA in CD$_3$OD with long range J filter width = 4 Hz.

Supplemental Figure S26. COSY spectrum of SSDA in CD$_3$OD.

Supplemental Figure S27. COSY enhanced spectrum of SSDA in CD$_3$OD with C6–H correlations.

Supplemental Figure S28. COSY enhanced spectrum of SSDA in CD$_3$OD.

Supplemental Figure S29. TOCSY spectrum of SSDA in CD$_3$OD.

Supplemental Figure S30. TOCSY enhanced spectrum of SSDA in CD$_3$OD with C6–H correlations.

Supplemental Figure S31. TOCSY enhanced spectrum of SSDA in CD$_3$OD.

Supplemental Figure S32. TOCSY enhanced spectrum of SSDA with view of C15–H correlations. Red circle represents missing correlation.

Supplemental Figure S33. HSQC–TOCSY enhanced spectrum of SSDA in CD$_3$OD.

Supplemental Figure S34. HSQC–TOCSY enhanced spectrum of SSDA in CD$_3$OD with C6–H correlations.

Supplemental Figure S35. HSQC–TOCSY enhanced spectrum of SSDA in CD$_3$OD.

Supplemental Figure S36. HSQC–TOCSY enhanced spectrum of SSDA in CD$_3$OD with spectral window.
Supplemental Figure S37. HSQC-TOCSY enhanced spectrum of SSDA in CD$_3$OD with C21–H and C27–H correlations.

Supplemental Figure S38. Amidation of SSDA with EDC and ethanolamine and chromatogram of first amidation product of SSDA.

Supplemental Figure S39. Chromatogram of second amidation product of SSDA.

Supplemental Table S1. qNMR Results

Supplemental Table S2. qNMR Results and step-by-step Workflow 100% Method to Determine Purity

Supplemental Table S3. qNMR Results and step-by-step Workflow IC Method to Determine Purity
Supplementary Methods

Description of chromatographic steps utilized for isolation and purification of M1

Initial Omnifit 10 cm C18 flash silica column purification. A 10 cm Omnifit chromatography column was charged with spherical C18 flash silica (45-75 μm, 70 Å) and activated with methanol on an Agilent 1100 series LC system at a flow rate of 5.0 mL/min for 30 minutes. The column was then equilibrated with a 95:5 H2O/MeOH solution at a flow rate of 5.0 mL/min for 30 minutes. 500 mL of urine was loaded onto the column at a flow rate of 5.0 mL/min. The column was washed with 50 mL of H2O. The column was eluted using a 50:50 H2O/MeOH with 0.1% NEt3, pH = 4.40 (adjusted using acetic acid) solution at a flow rate of 5.0 mL/min. 10 mL fractions were collected and a total of 12 fractions were collected. Fractions from each gallon were collected and kept separate from other gallons. The desired fractions were collected, combined, evaporated to dryness and the residue dissolved with 50 mL of 50:50 MeOH/10 mM NaOAc buffer, pH = 5.0.

LC-SCX-SPE purification. A 3 mL Supelclean LC-SCX SPE cartridge was attached to a vacuum manifold, activated with MeOH (6 mL) and equilibrated with 50 mM NaOAc buffer, pH = 5.0 (6 mL). The sample solution (10 mL of 50:50 MeOH/10 mM NaOAc buffer, pH = 5.0) was diluted to final volume of 100 mL using a water with 0.1% formic acid. The cartridge was charged with 10 mL of sample solution at a time (total of ten loadings) and each loading was collected in a separate 13x100 mm culture tube. The cartridge was charged with a 1.6% formic acid water solution v/v (6 mL) and the fraction was collected into a culture tube. The cartridge was charged with 80:20 50 mM NaOAc buffer, pH = 5.0/MeOH solution (8 mL, x3) and each fraction was collected in a separate culture tube. The M1 biomarker was eluted from the cartridge using a 50:50 MeOH/ NH4OH, 2-3% NH3 solution (6 mL) and collected in a culture tube. All collected fractions were evaporated and dissolved with 10 mL of 90:10 10 mM NH4OAc buffer, pH = 7.0/MeOH and analyzed. The desired fractions from each gallon were collected, combined, evaporated to dryness and the residue dissolved with 15 mL of 90:10 10 mM NH4OAc buffer, pH = 7.0/MeOH solution.

Second Omnifit 10 cm C18 flash silica column purification. A 10 cm Omnifit chromatography column was charged with spherical C18 flash silica (45-75 μm, 70 Å) and activated with methanol solution containing 0.1% triethylamine and 0.1% acetic acid on an Agilent 1100 series LC system at a flow rate of 5.0 mL/min for 20 minutes. The column was then equilibrated with a 95:5 H2O/MeOH (0.1% trimethylamine and 0.1% acetic acid) solution at a flow rate of 5.0 mL/min for 20 minutes. The sample was loaded onto the column 5 mL at a time (total of three columns used for each gallon). 25 mL fractions were collected and a total of 11 fractions were collected. Elution conditions for fractions 1-2 were 95:5 H2O/MeOH (0.1% triethylamine and 0.1% acetic acid); elution conditions for fractions 3-4 were 80:20 H2O/MeOH (0.1% trimethylamine and 0.1% acetic acid); elution conditions for fractions 5-7 were 60:40 H2O/MeOH (0.1% trimethylamine and 0.1% acetic acid); elution conditions for fractions 8-11 were 45:55 H2O/MeOH (0.1% triethylamine and 0.1% acetic acid). The desired fractions from each gallon were collected, combined, evaporated to dryness and the residue dissolved with 15 mL of 90:10 10 mM NH4OAc buffer, pH = 7.0/MeOH solution.

C18 Sunfire Column purification. A syringe loading injector (Rheodyne model 7125) was attached to an I-Class Acquity UPLC with a flow-through needle (FTN) sample manager. A Waters C18 Sunfire column (5.0 μm, 4.6 x 150 mm) equipped with a Waters Sunfire C18 VanGuard Precolumn (5.0 μm, 3.9 x 5 mm) was connected to the syringe loading injector. Two 500 μL manual injections of the M1 biomarker solution were loaded onto the head of the column (two volume equivalents of sample loop), column was disconnected from syringe loading injector, connected to sampled manager and equilibrated. The following gradient was used on
the UPLC system: initial conditions of 1% B, ramping up linearly to 99% B at 10 minutes and held for 2 minutes. At 12:10, the column was stepped down to initial conditions. Mobile phases A and B were H₂O and MeOH both containing 0.1% formic acid, respectively. The flow rate was 0.7 mL/min and column temperature was set to 25 °C. Fractions at 0-6, 6-6:20, 6:20-6:40, 6:40-7, 7-7:20, 7:20-7:40, 7:40-8, and 8-13 minutes were collected and analyzed. The desired fractions from each gallon were collected, combined, evaporated to dryness and the residue was dissolved with 3 mL of 90:10 10 mM NH₄OAc buffer, pH = 7.0/MeOH solution.

**Acquity UPLC BEH C18 Purification.** A syringe loading injector (Rheodyne model 7125) was attached to an I-Class Acquity UPLC with a flow-through needle (FTN) sample manager. A Waters Acquity UPLC BEH C18 column (1.7 μm, 2.1 x 100 mm) equipped with a Waters Acquity UPLC C18 VanGuard Precolumn (1.7 μm, 2.1 x 5 mm) was connected to the syringe loading injector. 250 μL manual injection of the M1 biomarker solution was loaded onto the head of the column (two volume equivalents of sample loop), column was disconnected from syringe loading injector, connected to sampled manager and equilibrated. The following gradient was used on the UPLC system: initial conditions of 1% B, ramping up linearly to 99% B at 5 minutes and held for 3 minutes. At 8 minutes, the column was stepped down to initial conditions. Mobile phases A and B were 90:10 10 mM (NH₄)(HCO₃) buffer, pH = 10/MeOH and MeOH (100%), respectively. The flow rate was 0.2 mL/min and column temperature was set to 25 °C. Fractions at 0-4:40, 4:40-5, 5-5:20, 5:40-6, 6-6:20, 6:20-6:40, 6:40-7, and 7-10 minutes were collected and analyzed. The desired fractions were collected, combined, evaporated to dryness and the residue dissolved with 1 mL of 50:50 MeOH/H₂O solution.

**Xevo G2–XS QToF mass spectrometer settings.** The Xevo G2-XS QToF mass spectrometer was operated in ESI+ mode. Analytes were separated on a Waters Acquity UPLC M-class trap symmetry C18 reversed-phase column (100 Å, 5 μm, 300 μm x 50 mm) and an iKey peptide BEH C18 column (130 Å, 1.71 μm, 150 μm x 50 mm). The following gradient was used on the UPLC system: trapping conditions of 97% A and 3% B with a flow rate of 30 μL/min. Initial conditions of 3% B ramping up linearly to 97% B at 5.0 min and held for 1 min. At 7.0 min, the column was stepped down to initial conditions. Mobile phases A and B were H₂O and CH₃CN both containing 0.1% formic acid, respectively. The flow rate was 3.0 μL/min and column temperature was set to 25 °C.
Supplemental Results

Isolation of M1 from pooled urine. Given that pH is a valuable tool to change charge states of a molecule and thereby enable various orthogonal separation methods, M1 stability was investigated under acidic, neutral and basic conditions and found to be stable under all conditions for several weeks. As the tertiary nitrogen in steroidal alkaloids is basic, we found that M1 could be retained on strong cation exchange SCX media, but the high salt content of human urine caused early breakthrough. Therefore, 700 mL of urine was loaded on an Omnifit preparative LC-column packed with C18 spherical flash chromatography particles and equilibrated with a 5:95 solution of methanol and water. After loading, the column was rinsed with approximately 10 column volumes of water to remove extremely polar metabolites and salts, and subsequently eluted with a 50:50 mixture of methanol/water resulting in ~100-fold concentration (see Table 1 in parent paper). Fractions were collected during elution and combined based on M1 content. This process was repeated until all 40 L of urine was processed. The volume of the combined fractions was evaporated to ~500 mL, and SCX solid phase extraction (SPE) was conducted to remove non-basic compounds. Fractions of 10 mL were extracted using a batched approach, yielding a total 150 mL of concentrated M1-containing solution. We explored whether strong anion exchange could be used to purify M1, however we were not able to release M1 from the stationary phase in high yield, thus this approach was abandoned. The solution was further purified by preparative chromatography on an analytical scale using a Sunfire C18 column. However, column performance dropped dramatically after only a few injections due to extremely hydrophobic compounds accumulating on the head of the chromatographic bed and irreversibly destroying the column. To address this issue an additional preparative step, analogous to that of step one using flash chromatography, was introduced to remove material that was detrimental for chromatographic columns operating with high efficiency. To purify M1 with high efficiency separation, 150 mL of effluent from the previous step was purified batch-wise on a Sunfire C18 analytical chromatography column with fraction collection. Although M1 was the most abundant molecule in the column effluent, it still was not sufficiently pure for NMR identification. In an attempt to introduce additional selectivity the pH of the mobile phase was changed to pH 10. It was found that M1 was significantly more strongly retained on a BEH C18 chromatographic column than all other interfering compounds that were also present. Small volume injections of M1 solution were purified batch-wise, maximizing the efficiency of the UPLC column to yield pure material by qTOF mass spectrometry and subsequently subjected to NMR analysis for structural elucidation.

Equation S1. Number of double bond equivalents.

\[ DBE = C - \frac{H}{2} + \frac{N}{2} + 1 \]
**Figure S1.** Enhanced view of $^1$H NMR spectrum of the solanidine showing four methyl resonances in CD$_3$OD. Insert showing C6-H ($\delta = 5.45$, $^3J_{\text{H-H}} = 5.6$ Hz, 1H) and C3-H ($\delta = 3.40$, m, 1H) resonances.

**Figure S2.** $^1$H spectrum of SSDA.
**Figure S3.** Enhanced view of $^1$H NMR spectrum of the unknown CYP2D6 biomarker showing four methyl resonances in CD$_3$OD. Insert showing methylidene resonance.

**Figure S4.** Stepwise connectivity model of unknown CYP2D6 biomarker. $a =$ Ambiguous assignment of C-1, C-2 and C-24. $X =$ C or heteroatom. Hydrogen atoms omitted for clarity.

**Figure S5.** Stepwise connectivity model of unknown CYP2D6 biomarker. $a =$ Ambiguous assignment of carbons 1, 2, 24. $X =$ C or heteroatom. Hydrogen atoms omitted for clarity.
Figure S6. 2D TOCSY with enhanced view of C2-H' correlations with C1-H' and/or C15-H'. Red circle represents missing C15-H correlation.
**Figure S7.** 2D TOCSY with enhanced view of C1-H' and C1-H correlations C2-H' and C2-H.

**Figure S8.** Stepwise connectivity model of unknown CYP2D6 biomarker. X = C or heteroatom. Hydrogen atoms omitted for clarity.
**Figure S9.** Stepwise connectivity model of unknown CYP2D6 biomarker. $X = \text{C or heteroatom}$. Hydrogen atoms omitted for clarity.

**Figure S10.** Stepwise connectivity model of unknown CYP2D6 biomarker. $X = \text{C or heteroatom}$; $R = \text{C or heteroatom}$; $R' = \text{C or heteroatom}$. Hydrogen atoms omitted for clarity.

**Figure S11.** Stepwise connectivity model of unknown CYP2D6 biomarker. $X = \text{heteroatom}$. Hydrogen atoms omitted for clarity.
Figure S12. $^{13}$C($^1$H) NMR spectrum of SSDA.

Figure S13. Enhanced $^{13}$C($^1$H) NMR spectrum of SSDA.
**Figure S14.** DEPT135 $^{13}$C-$^1$H NMR spectrum of SSDA.

DEPT135 $^{13}$C-$^1$H

(CD$_3$OD, 125 MHz)

SSDA

**Figure S15.** DEPT90 $^{13}$C-$^1$H NMR spectrum SSDA.

DEPT90 $^{13}$C-$^1$H

(CD$_3$OD, 125 MHz)

SSDA
Figure S16. HSQC full spectrum of SSDA in CD$_3$OD.

Figure S17. HSQC enhanced spectrum of SSDA in CD$_3$OD.
Figure S18. HMBC spectrum of SSDA in CD$_3$OD.

Figure S19. HMBC spectrum of SSDA in CD$_3$OD with C6–H correlations.
Figure S20. HMBC enhanced spectrum of SSDA in CD$_3$OD.

Figure S21. HMBC enhanced spectrum of SSDA in CD$_3$OD with C18–H, C19–H, C21–H and C27–H correlations.
Figure S22. HMBC spectrum of SSDA in CD₃OD with long range J filter width = 6 Hz.

Figure S23. HMBC enhanced spectrum of SSDA in CD₃OD with long range J filter width = 6 Hz.
Figure S24. HMBC spectrum of SSDA in CD$_3$OD with long range J filter width = 4 Hz.

Figure S25. HMBC enhanced spectrum of SSDA in CD$_3$OD with long range J filter width = 4 Hz.
Figure S26. COSY spectrum of SSDA in CD$_3$OD.

Figure S27. COSY enhanced spectrum of SSDA in CD$_3$OD with C6−H correlations.
Figure S28. COSY enhanced spectrum of SSDA in CD$_3$OD.

Figure S29. TOCSY spectrum of SSDA in CD$_3$OD.
Figure S30. TOCSY enhanced spectrum of SSDA in CD$_3$OD with C6–H correlations.

Figure S31. TOCSY enhanced spectrum of SSDA in CD$_3$OD.
Figure S32. TOCSY enhanced spectrum of SSDA with view of C15-H correlations. Red circle represents missing correlation.

Figure S33. HSQC–TOCSY enhanced spectrum of SSDA in CD$_3$OD.
Figure S34. HSQC–TOCSY enhanced spectrum of SSDA in CD$_3$OD with C6–H correlations.

Figure S35. HSQC–TOCSY enhanced spectrum of SSDA in CD$_3$OD.
Figure S36. HSQC–TOCSY enhanced spectrum of SSDA in CD$_3$OD with spectral window 2.5–1.5 ppm.

Figure S37. HSQC–TOCSY enhanced spectrum of SSDA in CD$_3$OD with C21–H and C27–H correlations.
Figure S38. Amidation of SSDA with EDC and ethanolamine and chromatogram of first amidation product of SSDA.
Figure S39. Chromatogram of second amidation product of SSDA.
Table S1. qNMR Results

<table>
<thead>
<tr>
<th>analyte</th>
<th>δ</th>
<th>number of protons (n)</th>
<th>Integral (Int)</th>
<th>Concentration of SSDA</th>
<th>Moles of SSDA</th>
<th>Amount of SSDA (μg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC</td>
<td>8.5000</td>
<td>2.000000000</td>
<td>2.000000000</td>
<td>0.00044152</td>
<td>0.00000022297</td>
<td>98.81</td>
</tr>
<tr>
<td>IC</td>
<td>7.7500</td>
<td>1.000000000</td>
<td>1.044700000</td>
<td>0.00042262</td>
<td>0.00000021343</td>
<td>94.68</td>
</tr>
<tr>
<td>IC</td>
<td>7.4000</td>
<td>2.000000000</td>
<td>2.114800000</td>
<td>0.00041755</td>
<td>0.00000021086</td>
<td>93.54</td>
</tr>
<tr>
<td>SSDA</td>
<td>6.6000</td>
<td>1.000000000</td>
<td>0.901600000</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IC = internal standard = pyridine, anhydrous, 99.8%

[IC] = internal standard concentration in NMR tube = 0.00048970 mol/L

Total volume of NMR sample = 505 μL

MW_{SSDA} = molecular weight of SSDA = 443.6187 g/mol

n_{IC} = number of protons that give rise to signal of internal calibrant

n_{SSDA} = number of protons that give rise to signal of SSDA

Int_{IC} = integral value of internal calibrant

Int_{SSDA} = integral value of SSDA

Sample calculation of concentration of SSDA = [pyridine] * [Int_{SSDA} / Int_{IC}] * [n_{IC} / n_{SSDA}] = 0.00044152 moles/L

Moles of SSDA = [SSDA] * [volume of solution] = 0.223 μmoles

Grams of SSDA = [moles of SSDA] * [MW_{SSDA}] = 98.81 μgrams
Table S2. qNMR Results and step-by-step Workflow 100% Method to Determine Purity

<table>
<thead>
<tr>
<th>analyte</th>
<th>δ</th>
<th>number of protons</th>
<th>integral</th>
<th>normalized integral (nInt)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSDA</td>
<td>6.600000000</td>
<td>1.000000000</td>
<td>0.901600000</td>
<td>90.1600</td>
</tr>
<tr>
<td>pyridine</td>
<td>8.500000000</td>
<td>2.000000000</td>
<td>2.000000000</td>
<td>100.0000</td>
</tr>
<tr>
<td></td>
<td>7.750000000</td>
<td>1.000000000</td>
<td>1.044700000</td>
<td>104.4700</td>
</tr>
<tr>
<td></td>
<td>7.400000000</td>
<td>2.000000000</td>
<td>2.114800000</td>
<td>105.7400</td>
</tr>
</tbody>
</table>

Equations taken from (Pauli et al. 2014)

\[ MW_{SSDA} = \text{molecular weight of SSDA} = 443.6187 \text{ g/mol} \]

\[ MW_{pyridine} = \text{molecular weight of internal calibrant} = 79.10 \text{ g/mol} \]

\[ nInt_{SSDA} = \text{normalized integral for SSDA signal (integral value normalized to value of number of protons)} = 90.16/1 = 90.16 \]

\[ nInt_{pyridine} = \text{normalized integral for pyridine signal (integral value normalized to value of number of protons)} \]

\[ \sum(nInt_{pyridine}) = \left\{ [(200.00/2 + 104.47/1 + 211.48/2)/5] = 62.04 \right\} \]

\[ \text{Purity} = P [\%] = \frac{nInt_{SSDA} * MW_{SSDA}}{nInt_{SSDA} * MW_{SSDA} + \sum(nInt_{pyridine} * MW_{pyridine})} * 100 = 99.85\% \]
Table S3. qNMR Results and step-by-step Workflow IC Method to Determine Purity

<table>
<thead>
<tr>
<th>Chemical shift (δ)</th>
<th>n (number of protons)</th>
<th>Int (integral value)</th>
<th>Concentration of SSDA [M]</th>
<th>Moles of SSDA</th>
<th>Amount of SSDA (µg)</th>
<th>Purity (%) of SSDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.54</td>
<td>2</td>
<td>2.0000</td>
<td>0.0004415</td>
<td>0.00000002230</td>
<td>98.91</td>
<td>99.8</td>
</tr>
<tr>
<td>7.85</td>
<td>1</td>
<td>1.0447</td>
<td>0.0004226</td>
<td>0.00000002134</td>
<td>94.68</td>
<td>99.8</td>
</tr>
<tr>
<td>7.44</td>
<td>2</td>
<td>2.1148</td>
<td>0.0004176</td>
<td>0.0000002109</td>
<td>93.54</td>
<td>99.8</td>
</tr>
<tr>
<td>6.56</td>
<td>1</td>
<td>0.9016</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Equations taken from (Pauli et al. 2014)

Internal calibrant = pyridine (concentration = 0.0004897 M)

Volume of solution (µL) = 505.00

mol$_{IC}$ = moles of internal calibrant

mol$_{SSDA}$ = moles of SSDA

m$_{IC}$ = mass of internal calibrant sample

m$_{SSDA}$ = mass of SSDA sample

P$_{IC}$ = purity of internal calibrant = 99.8%

n$_{IC}$ = number of protons that give rise to signal of internal calibrant

n$_{SSDA}$ = number of protons that give rise to signal of SSDA

Int$_{IC}$ = integral value of internal calibrant

Int$_{SSDA}$ = integral value of SSDA

MW$_{IC}$ = molecular weight of internal calibrant = 79.10 g/mol

MW$_{SSDA}$ = molecular weight of SSDA = 443.6187 g/mol

Molar ratio by intergrals = \[
\frac{mol_{IC}}{mol_{SSDA}} = \frac{\text{Int}_{IC}}{\text{Int}_{SSDA}} = \frac{\text{Int}_{IC} \cdot n_{SSDA}}{n_{IC} \cdot \text{Int}_{SSDA}}
\]

Purity = \[ P [\%] = \frac{n_{IC} \cdot \text{Int}_{SSDA} \cdot MW_{SSDA} \cdot m_{IC}}{n_{SSDA} \cdot \text{Int}_{IC} \cdot MW_{IC} \cdot m_{SSDA}} \cdot P_{IC} = 99.8 \%\]
Reference